Lantheus Holdings, Inc. announced a definitive agreement to sell its contract development and manufacturing organization (CDMO) business, including its Springfield, New Jersey facility, to PharmaLogic Holdings Corp. The transaction also includes a long-term supply agreement for a key therapeutic product.

Key Details

  • Transaction: The agreement, signed November 8, 2026, covers the sale of Lantheus's CDMO business and its manufacturing facility in Springfield, New Jersey.
  • Supply Agreement: The parties will enter a long-term supply deal where PharmaLogic's CDMO franchise, Agilera, will manufacture lutetium Lu 177 dotatate for Lantheus.
  • Transition & Closing: Lantheus will provide transition services to PharmaLogic following the sale, which is subject to customary closing conditions. Financial terms were not disclosed.